| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MUC1 (Mucin 1) and ICAM-1 (Intercellular Adhesion Molecule 1).
|
|---|---|
| ln Vitro |
MUC1, mucin core peptide binds to domain 1 of ICAM-1, an interaction that may mediate cell adhesion and signaling in cancer cells. MUC1 is a high-molecular-weight glycoprotein that is overexpressed and under-glycosylated in many carcinomas (breast, ovarian, pancreatic, lung, colon). The peptide sequence contains serine, threonine, and proline residues that can influence extended and helical structures. MUC1 contributes to immune evasion, metastasis, and chemoresistance.
|
| ln Vivo |
No in vivo activity data for this synthetic peptide is available. Studies on MUC1 biology often use full-length MUC1 protein or MUC1-expressing tumor cells. The MUC1 core peptide itself is not an active therapeutic agent but is used as a model for studying MUC1 structure, function, and immunogenicity. MUC1-derived peptides have been used as cancer vaccine candidates.
|
| Enzyme Assay |
Not applicable. A solid-phase binding assay can be used to study MUC1/ICAM-1 interaction. Recombinant ICAM-1 protein is immobilized on a 96-well ELISA plate at 2-5 microg/mL in PBS overnight at 4degC. Wells are blocked with 3% BSA for 2 h. MUC1 mucin core peptide (0-500 microM) is added to ICAM-1-coated wells and incubated for 2 h at room temperature. Bound peptide is detected by biotinylated anti-MUC1 antibody followed by streptavidin-HRP and TMB substrate. For direct binding, the MUC1 peptide is biotinylated and added to immobilized ICAM-1, and binding is detected by streptavidin-HRP. IC50 for inhibition of MUC1/ICAM-1 interaction is calculated.
|
| Cell Assay |
Human MUC1-positive cancer cells (e.g., MCF-7 breast cancer, T47D breast cancer, PANC-1 pancreatic cancer) are cultured in RPMI-1640 or DMEM with 10% FBS. Cells are seeded in 96-well plates (5×10⁴/well) and treated with MUC1 mucin core peptide (0-200 microM) or control peptides for 24-72 h. Cell viability is assessed by MTT assay. Alternatively, MUC1 core peptide (10-100 microM) can be used as a competitive inhibitor of MUC1-mediated cell adhesion. In adhesion assays, MUC1-expressing cells are pre-incubated with peptide (0-100 microM) for 30 min, then added to ICAM-1-coated wells. After 1 h, non-adherent cells are washed off, and adherent cells are quantified by crystal violet staining (OD 590 nm). Inhibition of adhesion is calculated.
|
| Animal Protocol |
No animal protocol is published. For cancer vaccine studies, female C57BL/6 mice or BALB/c mice are immunized subcutaneously with MUC1 mucin core peptide (50-100 microg) conjugated to a carrier protein (KLH or BSA) and emulsified in Freund's complete adjuvant (for priming) followed by incomplete adjuvant (for boosts). Boosts are given at 2-week intervals. Sera are collected for ELISA to measure anti-MUC1 antibody titers. Splenocytes are harvested for IFN-gamma ELISPOT to assess T-cell responses. For tumor challenge, MUC1-transgenic mice are implanted with MUC1-expressing tumor cells (e.g., MUC1-positive MC38 colon carcinoma), and peptide vaccination is evaluated for tumor growth inhibition.
|
| ADME/Pharmacokinetics |
No PK data reported. As a 16-amino acid peptide (MW ~1485 Da), the MUC1 mucin core peptide is rapidly degraded by proteases in serum and tissues, with an expected half-life of <1-2 h following systemic administration. The peptide is not intended for systemic therapeutic use and is primarily used in vitro or as an immunogen for antibody production. Its poor stability limits in vivo applications.
|
| Toxicity/Toxicokinetics |
No toxicity data reported for this peptide. Generic safety: Peptides derived from tumor-associated antigens such as MUC1 are generally well-tolerated as immunogens. In veterinary and human cancer vaccine studies, MUC1 peptide vaccines have shown no significant toxicity beyond mild injection site reactions. Cytotoxicity assays (e.g., LDH release) on cancer cells treated with MUC1 core peptide (up to 200 microM, 48 h) typically show no significant reduction in cell viability, indicating that the peptide itself is not directly cytotoxic.
|
| References | |
| Additional Infomation |
MUC1, mucin core peptide (CAS# 149205-73-2) is a synthetic research peptide corresponding to the tandem repeat region of the MUC1 protein (GVTSAPDTRPAPGSTA). MUC1 is a well-established tumor-associated antigen that is overexpressed in over 80% of human carcinomas, making it a target for cancer vaccine development and immunotherapies. The peptide is used for studying MUC1 structure, MUC1-ICAM-1 interactions, and as an immunogen to generate anti-MUC1 antibodies. This research-grade peptide is not a drug and has no clinical approvals.
|
| Molecular Formula |
C61H101N19O24
|
|---|---|
| Molecular Weight |
1484.56755423546
|
| Exact Mass |
1483.726
|
| CAS # |
149205-73-2
|
| PubChem CID |
9877219
|
| Appearance |
White to off-white solid powder
|
| LogP |
-11.7
|
| Hydrogen Bond Donor Count |
22
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
104
|
| Complexity |
3160
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)CN)O
|
| InChi Key |
WDLOVECVQSOHLL-UIXJRKFUSA-N
|
| InChi Code |
InChI=1S/C61H101N19O24/c1-26(2)43(74-40(86)22-62)53(96)77-46(32(8)85)56(99)73-36(25-82)48(91)67-27(3)57(100)79-19-11-16-39(79)52(95)72-34(21-42(88)89)47(90)75-45(31(7)84)55(98)71-33(13-9-17-65-61(63)64)59(102)80-20-12-15-38(80)51(94)68-28(4)58(101)78-18-10-14-37(78)50(93)66-23-41(87)70-35(24-81)49(92)76-44(30(6)83)54(97)69-29(5)60(103)104/h26-39,43-46,81-85H,9-25,62H2,1-8H3,(H,66,93)(H,67,91)(H,68,94)(H,69,97)(H,70,87)(H,71,98)(H,72,95)(H,73,99)(H,74,86)(H,75,90)(H,76,92)(H,77,96)(H,88,89)(H,103,104)(H4,63,64,65)/t27-,28-,29-,30+,31+,32+,33-,34-,35-,36-,37-,38-,39-,43-,44-,45-,46-/m0/s1
|
| Chemical Name |
(3S)-3-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 27.5 mg/mL (18.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6736 mL | 3.3680 mL | 6.7360 mL | |
| 5 mM | 0.1347 mL | 0.6736 mL | 1.3472 mL | |
| 10 mM | 0.0674 mL | 0.3368 mL | 0.6736 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
